Gene Logic Announces Addition of new Human Gene Expression Data

Gene Logic Inc. has announced the completion of significant enhancements to its gene expression capabilities, used by pharmaceutical and academic researchers to characterize drug targets and understand the relationship between gene expression and disease.

Gene Logic claims that its customers will benefit from the systems in several ways:

- The Affymetrix GeneChip^® Human Genome U133 Plus 2.0 Array is designed to offer increased accuracy and reproducibility, and uses less sample RNA than its predecessors.

- Guided by customer feedback, Gene Logic ran 10,000 of the most in-demand human samples on the microarray to increase the content of the Company's proprietary BioExpress^® System.

Additionally, the company runs all human samples on the new array and incorporates the data in the BioExpress System.

- Gene Logic's Microarray Data Generation and Analysis Services now generate reproducible genomic data from the array in a high-throughput, robotic environment.

- For superior analysis of the human gene expression data, Gene Logic recently expanded its GX^® Gene Index to include several million updated gene and protein annotations as well as 650 biological pathways, most of which are exclusive to Gene Logic through an agreement with BioCarta.

Lianne McLean, senior director, Product Marketing at Affymetrix said, "For the last seven years, Affymetrix and Gene Logic have been working together to help researchers better understand the relationship between gene expression and disease."

"With the addition of the GeneChip Human Genome U133 Plus 2.0 Array, Gene Logic customers will have access to both the gold-standard microarray technology and the industry leading expression database."

Dennis Rossi, senior vice president and general manager, Genomics for Gene Logic, said, "To meet the changing needs of our customers and continue to provide the high-quality gene expression and SNP genotyping services they demand, Gene Logic has improved one of the largest commercial microarray labs in the world."

"Guided by our prior experience gained from processing more than 170,000 microarrays, we refined our operations using robotics, high-throughput process automation, and strict quality metrics."

"As a result of upgrading our content and expanding our microarray production facilities, we now offer these expanded capabilities to pharmaceutical, biotech, and government customers to outsource data generation and analysis work."